UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Negotiating call pay: Money for nothing or your time for free

Gynecologic oncology, 2017-06, Vol.145, p.166-166

2017

Volltextzugriff (PDF)

Telemedicine and patient navigation: Effective strategies to deliver regional genetic counseling

Gynecologic oncology, 2017-06, Vol.145, p.147-148

2017

Volltextzugriff (PDF)

A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650)

Gynecologic oncology, 2015-04, Vol.137, p.5-6

2015

Volltextzugriff (PDF)

Ureteral Injury: Avoidance and Prevention

Journal of minimally invasive gynecology, 2012-11, Vol.19 (6), p.S172-S172

2012

Volltextzugriff (PDF)

Closure of the Vaginal Cuff after a Total Laparoscopic Hysterectomy (TLH) with a Running Barbed Suture

Journal of minimally invasive gynecology, 2011, Vol.18 (6), p.S84-S85

2011

Volltextzugriff (PDF)

Laparoscopic Vaginal Cuff Closure Comparing Endostitch to the RD-180

Journal of minimally invasive gynecology, 2010-11, Vol.17 (6), p.S76-S77

2010

Volltextzugriff (PDF)

Development of a Proficiency-Based Vaginal Cuff Closure Simulator Curriculum

Journal of minimally invasive gynecology, 2011, Vol.18 (6), p.S87-S87

2011

Volltextzugriff (PDF)

Opportunistic salpingectomy would significantly reduce ovarian cancer mortality and would reduce overall healthcare expenditures

Gynecologic oncology, 2019-06, Vol.153 (3), p.e11-e12

2019

Volltextzugriff (PDF)

818TiP REFRaME-O1/ENGOT-OV79/GOG-3086: A phase II/III open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice of chemotherapy in women with relapsed platinum-resistant epithelial ovarian cancer expressing folate receptor alpha (FolRα)

Annals of oncology, 2023-10, Vol.34, p.S540-S541

2023

Volltextzugriff (PDF)

Minimally Invasive Technique Not Associated with Worse Prognosis in Patients with Stage I Uterine Papillary Serous Carcinoma (UPSC)

Journal of minimally invasive gynecology, 2022-11, Vol.29 (11), p.S21-S21

2022

Volltextzugriff (PDF)

Molecular profiling in a large cohort of gynecologic neuroendocrine tumors

Gynecologic oncology, 2020-10, Vol.159, p.262-262

2020

Volltextzugriff (PDF)

Compensation differences by gender in gynecologic oncology

Gynecologic oncology, 2020-10, Vol.159, p.9-9

2020

Volltextzugriff (PDF)

Perioperative recovery from laparoscopic versus robotic surgery for endometrial cancer

Gynecologic oncology, 2020-10, Vol.159, p.233-234

2020

Volltextzugriff (PDF)

Comparison in outcomes between minimally invasive sentinel nodes versus full laparoscopic lymphadenectomy for endometrial cancer

Gynecologic oncology, 2020-10, Vol.159, p.227-227

2020

Volltextzugriff (PDF)

Enhanced recovery after surgery (ERAS) does not have a significant impact after minimally invasive surgery in gynecologic oncology

Gynecologic oncology, 2020-10, Vol.159, p.281-281

2020

Volltextzugriff (PDF)

The (f)utility of therapy in ovarian cancer after the development of platinum resistance

Gynecologic oncology, 2020-10, Vol.159, p.105-106

2020

Volltextzugriff (PDF)

Factors associated with same day discharge (SDD) after laparoscopic surgery in gynecologic oncology

Gynecologic oncology, 2020-10, Vol.159, p.280-280

2020

Volltextzugriff (PDF)

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)

Annals of oncology, 2014-04, Vol.25 (4), p.852-858

2014

Volltextzugriff (PDF)

433 - Minimally Invasive Surgery during Pregnancy

Journal of minimally invasive gynecology, 2017-11, Vol.24 (7), p.S180-S180

2017

Volltextzugriff (PDF)

Minimally Invasive Surgery during Pregnancy

Journal of minimally invasive gynecology, 2017-11, Vol.24 (7), p.S180

2017

Volltextzugriff (PDF)

741MO Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion

Annals of oncology, 2023-10, Vol.34, p.S508-S508

2023

Volltextzugriff (PDF)

A phase Ib study of navicixizumab and weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer

Gynecologic oncology, 2020-10, Vol.159, p.14-15

2020

Volltextzugriff (PDF)

818TiP Balstilimab alone or in combination with zalifrelimab as second-line treatment for patients with previously treated recurrent/metastatic cervical cancer (R/M CC): A randomized, placebo-controlled phase II trial (RaPiDS/GOG-3028)

Annals of oncology, 2021-09, Vol.32, p.S769-S770

2021

Volltextzugriff (PDF)

A cost-effectiveness analysis of universal genetic testing for common hereditary cancer mutations in women compared with family history-based testing

Gynecologic oncology, 2019-06, Vol.154, p.203-203

2019

Volltextzugriff (PDF)

Workplace and sexual harassment and discrimination in gynecology

Gynecologic oncology, 2019-06, Vol.154, p.10-10

2019

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(49)
Buchkapitel
(2)

Sprache

Englisch
(49)
Deutsch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Gynecologic Oncology
(28)
Journal Of Minimally Invasive Gynecology
(10)
Annals Of Oncology
(8)
Physics Letters. B
(2)
Annals Of Allergy, Asthma, & Immunology
(1)

Menü

Weitere Dienste

Einstellungen

Negotiating call pay: Money for nothing or your time for free

Telemedicine and patient navigation: Effective strategies to deliver regional genetic counseling

A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650)

Ureteral Injury: Avoidance and Prevention

Closure of the Vaginal Cuff after a Total Laparoscopic Hysterectomy (TLH) with a Running Barbed Suture

Laparoscopic Vaginal Cuff Closure Comparing Endostitch to the RD-180

Development of a Proficiency-Based Vaginal Cuff Closure Simulator Curriculum

Opportunistic salpingectomy would significantly reduce ovarian cancer mortality and would reduce overall healthcare expenditures

818TiP REFRaME-O1/ENGOT-OV79/GOG-3086: A phase II/III open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice of chemotherapy in women with relapsed platinum-resistant epithelial ovarian cancer expressing folate receptor alpha (FolRα)

Minimally Invasive Technique Not Associated with Worse Prognosis in Patients with Stage I Uterine Papillary Serous Carcinoma (UPSC)

Molecular profiling in a large cohort of gynecologic neuroendocrine tumors

Compensation differences by gender in gynecologic oncology

Perioperative recovery from laparoscopic versus robotic surgery for endometrial cancer

Comparison in outcomes between minimally invasive sentinel nodes versus full laparoscopic lymphadenectomy for endometrial cancer

Enhanced recovery after surgery (ERAS) does not have a significant impact after minimally invasive surgery in gynecologic oncology

The (f)utility of therapy in ovarian cancer after the development of platinum resistance

Factors associated with same day discharge (SDD) after laparoscopic surgery in gynecologic oncology

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)

433 - Minimally Invasive Surgery during Pregnancy

Minimally Invasive Surgery during Pregnancy

741MO Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion

A phase Ib study of navicixizumab and weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer

818TiP Balstilimab alone or in combination with zalifrelimab as second-line treatment for patients with previously treated recurrent/metastatic cervical cancer (R/M CC): A randomized, placebo-controlled phase II trial (RaPiDS/GOG-3028)

A cost-effectiveness analysis of universal genetic testing for common hereditary cancer mutations in women compared with family history-based testing

Workplace and sexual harassment and discrimination in gynecology

Suchergebnisse filtern